Skip to main content
. Author manuscript; available in PMC: 2012 Dec 15.
Published in final edited form as: Cancer Res. 2011 Oct 11;71(24):7376–7386. doi: 10.1158/0008-5472.CAN-11-1154

Figure 3. Biomarker Potential of Bladder Cancer-associated Metabolites in Urine.

Figure 3

A. Overview of the strategy used to develop and validate the Partial Least Square-Discriminate Analysis (PLS-DA)-based metabolomic model for delineating benign and BCa in urine. B. Receiver Operator Characteristic (ROC) Curve describing the ability of PLS-DA model using 25 BCa-associated metabolites (M) to delineate benign and BCa in urine C. Same as in B, but for combination of BCa-associated metabolites (M) and urine cytology (UC) in delineating benign and BCa in urine. D. Same as in B, but for muscle-invasive (n=8) and non-muscle invasive (n=20) BCa in Group 2 (UM cohort).